(.....

24 I - - 2012

H,
5 , -

ditorial

9
10

-
& ..:
:
1 : 1
:

:

12

18

(P) 2012

21

50

22

(3 )

6
7
7
8

26
28
31

.....
5 :
/
5
:
: ...

34
34

X . : |
: |

24

(.....)

24 - - 2012

.....

: / . .
: / ... -
. : / ..
: T /
: / ,
/ .. ,
/ ..

.....

99,
115 27
./fax: 210 7753104
e-mail: pefni@ ath.forthnet.gr
http://www.pefni.gr

, , ,
, , , ,
, , ,
, , ,

MasterPrint

editorial


( editorial)

, ,
.
,
. , , ,
( ),
.
: , , , , , ,
, , , ,

. ,

, , ,
.
,
,
-

.
:
, .
,
.

:

 ,

,

,
 ,
,

, ' ,


.
,

, .
, . ;
1.  , ,
.
2.  .
3. .
4. 
.
5.  .
6.  .
7. , .
, 5 .., , .

 -
& ..

:
, 01.06.2012
. .: 3 //. 56384

&

/

. : 17, 10187
: 210-5238740, 5235908, : 210-5230577
:
1.  &

2. 
3. -- ( )
:
SSL
(https)
Internet.
, ,

:

(.. 3G, HSPA), 30.06.2012.

INTERNET (.. WI-FI
), 30.06.2012.
 ,
,
,
01.06.2012.
. 3/ 55427/30.05.2012 ' . 3/ 55430
& : 1
2012 1
,
.

.
O

, , ,
:

, Registration,

e-syntagografisi.

registration ,
.
O
&

 -


, :
,
, ,
,
.

, .

, ,
,
.

1
1
, 03.07.2012
. .: . 13659

&

1
/ &
. . . & . .

. : 3,
115 21
: .
: 213-2010445
: 213-2010434
:
1. 1
2. 
:
1
.: ' . 12103/24.05.2011 .

1 ,
:

, ,
.

(. . 5/ . 75762, 1037/. /
21.07.2005).
1
,
( 6),
.
.
.. ,
( - - ), . ,

.
.
O

 -




, 15.06.2012
. .: 4679




. /: 3
. : 115 21,
: .
: 213 2010586 402
Fax: 213 2010418
:
1. .. .. (
)
2. ..
. 9 . 3580/2007
:





(),

:
1.  (3) , (5) (6)
, .
2.
 ..
.
3.

(4) (
18 ), , ,

.

4.  , ,
,
,
3 , - . .
5.
 ,
.
6.

.
7.  -
,
.
8.
 , ,
.
9.


,
.
10.  ,

,

,
,
.

.

 -
- -
1. 
,
,
, .
2. ,
,

, .
3.
 () , , , , .
4. 
,
.
5.  ,
, -

.
6.
 ,
.
7. 
.
8.


,
,

.
9.
 L.I.S. .

:

(ATC: J06BA02 J06BA01)
30% ,
, , .
: GAMMACARD SD, INTRATECT,
IGVENA, INTRAGLOBIN, PENTAGLOBIN, SUBCUVIA,
GAMINEX, PRIVIGEN, KIOVIG HIZENTRA
12.06.2012

.

,
, .

, ,
.

 -
:

, 14.09.2012
. .: 65541



284, 155 62
www.eof.gr
:

:
: .
: 213-2040540
Fax: 210-6549500
:

,

,

,


.

.

(-

10

,
,
..).

. 3324/2003 19 . 4. . .
'

,
( )
.
, ,


.
.
.

.....
. Giuseppe Carone, Head of Unit European Commission, Directorate General Economic and Financial Affairs.
:

Panhellenic Association of Hospital Pharmacists

99, Michalakopoulou st.
115 27 Athens
Dear Ms. Irene Tsikalaki, Dear Ms. Despoina Makridaki,

Brussels, 27 August 2012

Thank you very much for your letter of 13 Jul 2012 informing us of the current status of hospital pharmacies in Greece.
We take note of the information you provide in the letter and which we find very useful.
We will look carefully into the issues you raised and, more generally, into the policies being proposed during the series
of meetings with the Greek government reviewing the policy progress vis--vis the Memorandum of Understanding
with Greece.
Yours respectfully,

Giuseppe Carone

.
excel www.pefni.gr:

,
EXCEL .
(D) ( + 5% + ) ENTER
, .
, .
.

12

, :

, , (ESOT)
. ( tacrolimus), mTOR (sirolimus everolimus)
( ).
, , . ,
, . , , .
, , , ,

.
. ( 2010) (European Medicines Agency EMA)
80%-125% 90%-111%.
, ,
90% 111% , ,
. ,
, , , , .
ESOT
().
.
.

13

, ( )
,
(.. ) .


:
1.
 , ,
.
2.
 , .
3.  , .
,
, , .
4.
 ,
, , .
5.
 ,

(European Medicines Agency EMA) .
6.
 .

1. D
 uh MS, Cahill KE, Paradis PE, Cremieux Py, Greenberg PE. The economic implications of generic substitution of antiepileptic drugs: a review of recent
evidence. Expert Opin Pharmacother 2009; 10: 2317.
2. V
 ersantromt C, Maliepaard M, Lekkerkerker F. Generics: what is the role of registration authorities. Neth J Med 2008; 66: 62.
3. C
 hristians U, Klawitter J, Clavijo CF. Bioequivalence testing of immunosuppressants: concepts and misconceptions. Kidney Int Suppl 2010; 115: S1.
4. U
 ber PA, Ross HJ, Zuckermann AO, et al. Generic drug immunosuppression in thoracic transplantation: an ISHLT educational advisory. J Heart Lung
Transplant 2009; 28: 655.
5. D
 uerden MG, Hughes DA. Generic and therapeutic substitutions in the UK: are they a good thing? Br J Clin Pharmacol 2010; 70: 335.
6. A
 lameri M, Epstein M, Johnston A. Generic and therapeutic substitutions: are they always ethical in their own terms? Pharm World Sci 2010; 32: 691.
7. J ohnston A. Challenges of therapeutic substitution of drugs for economic reasons: focus on CVD prevention. Curr Med Res Opin 2010; 26: 871.
8. V
 an Gelder et al. ESOT guidelines on generic substitution. Transplant International; 24 (2011): 1135-1141.

14

1 2

:

, 20 2012
,
. Focus-Bari
, , ,
, ,
, .
, 7 10
( , ), ()
( ).
, 10 .
,
. ,
, ,
.
, . ,
:
.
, , , .

. 60 ,
,
, . , ....
,
, , . ,
, offline
, internet, , .
2012 800 ( 1.696.000

15

), 35-70 , .
(...) , 20
() (branded generics)
60 .
8.500 , , ,
, / . , .
:
, : 210 52 47 139, 693 60 64 551
, Run Communications: 215 56 05 247

FRESENIUS KABI HELLAS , :

A: Fresenius Kabi Hellas A.E.

:
:
26.06.2012
,
Fresenius Kabi Hellas 1999,
( ), (, ..).

, Frensius Kabi Hellas ,
,
. , ,
.
, , 2007-2009,
rebate, .
,
, . ,
(), .
,
.

16

,
, .
,
.
.
,

Fresenius Kabi Hellas

DEXTROSE INJECTION/FRESENIUS 5% w/v, , 100ML

DEXTROSE INJECTION/FRESENIUS 5% w/v, , 250ML
DEXTROSE INJECTION/FRESENIUS 5% w/v, , 500ML
DEXTROSE INJECTION/FRESENIUS 5% w/v, , 1000ML
DEXTROSE INJECTION/FRESENIUS 10% w/v, , 1000ML
ELECTROL YTE/FRESENIUS1 (6,4+5,00+0,75+0,75+0,35+0,31)%, , 500ML
LACTATED RINGERS INJECTION/FRESENIUS, (3,1+0,3+6+0,2)G, , 500ML
LACTATED RINGERS INJECTION/FRESENIUS, (3,1+0,3+6+0,2)G, , 1000ML
MANNITOL/FRESENIUS, 20%, , 500ML
POTASSIUM CHLORIDE IN DEXTROSE INJECTION/FRESENIUS 15%+0,2%, , 1000ML
SODIUM CHLORIDE 0.18% & DEXTROSE 4%/FRESENIUS, , 250ML
SODIUM CHLORIDE INJECTION/FRESENIUS, , 0,9% W/V, 100ML
SODIUM CHLORIDE INJECTION/FRESENIUS, , 0,9% W/V, 250ML
SODIUM CHLORIDE INJECTION/FRESENIUS, , 0,9% W/V, 500ML
SODIUM CHLORIDE INJECTION/FRESENIUS, , 0,9% W/V, 1000ML
SODIUM CHLORIDE INJECTION/FRESENIUS, , 0,9% W/V, 100ML FREEFLEX
WATER FOR INJECTION/FRESENIUS, , 1000ML

METROGYL, , 500MG/100ML
PACLITAXEL/KAB, 6mg/ML, 30MG
PACLITAXEL/KABI, 6mg/ML, 6mg/ML, 100MG
GEMCIRENA, , 38mg/ML, 200MG
GEMCIRENA, , 38mg/M, 1G
OXALIPLATIN/KABI , 5mg/ml, 50MG
OXALIPLATIN/KABI , 5mg/ml, 100MG
CIPROFLOXACIN/KA, , 100MG/SOML
CIPROFLOXACIN/KABI, , 200MG/100ML
CIPROFLOXACIN/KABI, , 400MG/200ML
LEVOFLOXACIN/KABI, , 5MG/ML
PROPOFOL MCT/LCT/FRESENIUS 1% (10MG/1ML), , 520ML
PROPOFOL MCT/LCT/FRESENIUS 1% (10MG/1ML), , 50ML
PROPOFOL MCT/LCT/FRESENIUS 1% (10MG/1ML), , 100ML
PROPOFOL MCT/LCT/FRESENIUS 2% (20MG/1ML), , 50ML

17

-

(EAHP) 2012
.

EAHP , ,
, 32 - EAHP.

Roberto Frontini () Tony West (
), , . , Tajda Miharija
Gala () Kees Neef () , EAHP ,
Elfriede Dolinar () Vagn Handlos ().
, Francesca Venturini
Petr Horak () Joan Peppard ().
:

()
.

EAHP ,
.
, ,
, ,
.

(EAHP)
() 15 16 2012.
58
29 - EAHP. ..
.


, -

18

EAHP ( 31 ) :

)  ,

,
,

-
)  (, )


,
) 
,


EAHP
.. .
(Biotechnology, Evidence-Based edicine, Aspects of
Compounding, Management)
2009 2012,
, , . , ,

(Master) .
-

2013, ,
.
2010
EAHP
. Tajda Miharija Gala
EAHP 2010 .
EAHP (www.eahp.eu).

.

,
(barcode) , .


EAHP (www.eahp.eu).

International Breast Ultrasound Course 2013 (IBUS 2013)

Multimodality Imaging & Interventional Techniques
arranged by the International Breast Ultrasound School
in conjuction with the Scientific Society of Breast Diseases
May 20th-22nd, 2013, IASO Maternity Hospital Lecture Room, Maroussi, Athens
3 / 13-15 2013
, . ,

19


50

50 ,

.
. .

.
,

.


Mega.
. . ,
-

( ,
, , .) .
.. 4 , ,

.
.

, , , .
, ,
,
,
.
: ygeia360.gr,

JCIA
, ,
.
6984507090
e-mail info@eurosynapses.eu www.eurosynapses.eu
.

21


(3 )
, .

... | 200

 : 2 [ 2
].
 : 3 [

(1)].
 .
 ,

.

.
 ,
.

: :
: ;

... | 115

22

 : 4 [

(1) (1) ].
 ,

.
online .

220 .


.
.

21-23 2012
S ,

21 2012
17:00-19:00 5
19:30

20:00-21:00 | PROFESSOR OF MEDICINE IMMUNOLOGY

E.K..
: |
22 2012

8:30-10:00
( 20 & 21/9/2012 :
)
10:00-10:45 |

: :
;
10:45-11:00 N | MBA, Pharm. D.
REGULATORY AFFAIRS BUSINESS DEVELOPMENT MANAGER
: ,

11:00-11:30
....
: ...
11:30-12:00 | IK , / HEALTH DATA SPECIALISTS
: ...
12:00 -12:30 |
/H , /
: ; ;
12:30-13:00 -
13:00-18:00 -

24

22 2012

18:00-18:30 -
& ,
, ,

:
18:30-19:00
-
,
:

19:00-20:00
:
: |
| .....
| .. ....
| ...
| ...

23 2012
09:00-11:30
- ,
11:30
: ..
()
:
:
. :
: () - ()
: , ,
...

25

2012
(20-21 2012) 5
(21-23 2012), (),
S, -, , .
2012
(20-21 2012) , , , , (), , ...
.
5
(21-23 2012),
, , .

()
www.pefni.gr .

K 5
,
5
-.

, .

, ,
,
.

26

(, )
.
,

.
,
.

. , ,
,
.
, .
,
.
,
,
. ,


.
, , .
.
,
,

,
.
(
). , ,
.
. .

,
. ,
.

,
. , , , , .
, , .
, ,

.
,
,
.

, , .

.
,
.

..

27




.

.
1 , ,
(
). 2000-2008 6,9%, 3,8%. ,
.

, 2000-2008 (%)

1:

, 2000-2008 (%)

,

.
,
,
.
- ,
-

28

.
- .
,
- ,
(, )


.
(cost-effectiveness).

,
.
.
,

. ..

.



,
. ,
.
, .
,
,
.
, ,

.
(performance indicators)
,
(clinical effectiveness).

- ,
,

.


(P) (Q).
:
( ),
 ( , )
(..).
- (Q)
,
, , .

,
,
. (Health Technology
Assessment) (. 1),

.

1:

x
x

*
x
x

29

, ( 2).

,

. 2
' .

2:

.
, :

30

.
 .
 .
 .

.
 .
 .
 .
 .

, , .
, ,
,
. ,
,
,
.
, ,
.
,
,

pdf :
www.pefni.gr


...


.
,
.
,
.

,
.
, ,
NICE (National Institute for
Clinical Excellence) . ,

:

 ,
;
 ;

,
.
. ,

. , ,
.
,

,
,
.
:

 ,


,

.

14 (..) :


...,

,


/
.

: 155 7
. 68,0% 5
-

31


.
6 ,
... 31 . 49,7% , ,
6,4%, 20,0% 23,9% ,
. (57,3%)
(20,0%)
. (
/ ) 43,9% 49,7%
, .
22.012

, (,
, )
(. ).

(%)

(%)

()

43%

43%

29.373

52%

43%

25.422

52%

48%

21.855

50%

57%

26.639

42%

58%

14.868

-
,

, .
.

32

. ..
80,8% ,
,
19,2%.

, 74%.

, ,
,


.


Health Data Specialists

: .

: . , .. /,
. , .. ..., . , ..
. , ,

: . , .

: . ,

33


.
|
.....,
, ,
.
- ,
' .
.
,

|
... .
, , . .
,
52 , 2009, 27,
.
.
: : 14x21 | : 152 | : 12.
: 210 9587083 | 6984 911622

|
1957 .
()
. ,
. .
1995 . , (1999).
.
, 10 - 9,31.
2010 .
, Vivere pericolosamente:
26 Una storia obscura.
2011 .

T EJHP, ,

/ / : http://www.eahp.eu/user/login

34